MedPlus Health hit a fresh 52-week high of ₹1,052.05 today after posting stellar Q4 results. The company’s consolidated net profit jumped 54% year-on-year to ₹52 crore for the quarter ending 31 March 2025. That’s not all—profit before tax (PBT) soared 91.1% YoY to ₹61.12 crore.
EBITDA stood at ₹80.33 crore, up 38.2% from ₹58.13 crore in Q4 FY24. Operating margins also improved to 5.3% from 3.9%. In simple terms? MedPlus isn’t just growing—it’s getting leaner and meaner too.
What does this mean for everyday people?
More stores, better margins, and rising profits mean MedPlus is expanding fast while keeping operations tight. The company added 100 new stores this quarter, pushing its total count to 4,712 across India. That’s more access to meds, diagnostics, and wellness products for people in more places.
When the business grows smartly, it usually passes some of that efficiency down to customers. Whether it’s through better prices, better access, or better services—this kind of performance often makes a visible difference on the ground.
Also Read LIC Shares Jump 3% on Mixed Q4: Time to Buy, Hold, or Sell?
A healthy dose of good news
On a full-year basis, the numbers look even more impressive. MedPlus Health’s FY25 net profit jumped 129.6% to ₹150.32 crore. Revenue rose by 9.1% YoY to ₹6,136.05 crore. The brand isn’t just surviving the market—it’s thriving in it.
Meanwhile, the board announced the appointment of Subrahmanyam Sharma Tatapudi as the new Chief Technology Officer (CTO), effective 27 May 2025. Previously the Deputy CTO, his elevation signals a continued focus on tech-driven growth—especially in a market where digital healthcare is booming.
MedPlus isn’t your average chemist. It operates in retail and wholesale, imports and manufactures private-label wellness products, and even runs full-fledged diagnostic centers. Its hybrid model—online and offline—is giving it a strategic edge in a fragmented industry.
That hybrid approach could be why investors are giving it a clean bill of health.
While many brick-and-mortar retailers are still figuring out their post-pandemic plans, MedPlus is quietly becoming a textbook case of how to do scale with precision. In a market full of sickly balance sheets, this one’s looking ripped.
Also Read Belrise Industries Shares Open Strong at ₹100: Buy, Sell or Just Hold Tight?
